Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

Gillen Oarbeascoa, MD, Sara Redondo, MD, Maria Jose Morán-Jiménez, MD, Amalia Domingo, MD, Cristina Muñoz-Linares, MD, Maria Isabel Moreno-Carralero, MD, Jose Maria Bellon, Juan Francisco del Campo Rincon, MD, Jose Luis Díez-Martín, MD PhD, Patricia Font, MD

Blood (2018) 132 (Supplement 1): 3085.

https://doi.org/10.1182/blood-2018-99-116992

Published: 2018

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

Idiopathic Cytopenia of Undetermined Significance (ICUS): Impact of Flow Cytometry Immunophenotyping (FCI) in the Diagnosis of Myelodysplastic Syndrome (MDS) When Morphology Is Not Conclusive.

Patricia Font, MD, Dolores Subira, PhD, Javier Loscertales, MD, Eva Arranz, PhD, Arancha Alonso, MD, M. Angeles Perez-Saenz, PhD, Antonio Escudero, PhD, Jose Maria Fernandez-Rañada, PhD, Teresa Vallespi, PhD

Blood (2007) 110 (11): 2467.

https://doi.org/10.1182/blood.V110.11.2467.2467

Published: 2007

Journal Articles

Immunophenotype in Chronic Myelomonocytic Leukemia: Is It Closer to Myelodysplastic Syndromes or to Myeloproliferative Disorders?.

Dolores Subira, MD, PhD, Patricia Font, MD, Lucia Villalon, MD, Elena Gongora, MD, Cristina Serrano, MD, Mario Rodriguez-Paíno, MD, Elham Askari, MD, Susana Castañon, Tch, Raquel Gonzalo, Tch, Alejandro Roman, MD, Pilar LLamas, MD PhD, Ana Villegas, MD Phd

Blood (2007) 110 (11): 4621.

https://doi.org/10.1182/blood.V110.11.4621.4621

Published: 2007

Journal Articles

Phenotypic Aberrations of Myeloid CD34+ Cells in Patients with Myelodysplastic Syndrome (MDS): Clinical Significance and Correlation with Cytogenetics Abnormalities.

Dolores Subira, MD, PhD, Patricia Font, MD, Eva Arranz, MD, PhD, Ramiro B Soraya, Susana Castanon, TcH, Mónica Renedo, MD, PhD, Carlos Blas, MD, Maria F. Garcia B, Olga Gonzalez B, José F. Tomas, MD, PhD, José M. Fernandez-Rañada, MD

Blood (2004) 104 (11): 2374.

https://doi.org/10.1182/blood.V104.11.2374.2374

Published: 2004

Journal Articles

Flow Cytometry Applications in the Diagnosis of Myelodysplastic Syndrome (MDS): Analysis of 45 Cases.

Patricia Font, MD, Dolores Subira, MD, PhD, Maria C. Martinez-Chamorro, MD, PhD, Susana Castañon, Juan Lopez-Pascual, MD, PhD, Arancha Alonso, MD, Maria A. Perez-Saenz, MD, PhD, Juan J. Gil-Fernandez, MD, PhD, Concepcion Alaez, MD, Antonio Escudero, MD, PhD, Jose F. Tomas, MD, PhD, Jose M. Fernandez-Rañada, MD, PhD

Blood (2004) 104 (11): 4724.

https://doi.org/10.1182/blood.V104.11.4724.4724

Published: 2004

NARROW

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Idiopathic Cytopenia of Undetermined Significance (ICUS): Impact of Flow Cytometry Immunophenotyping (FCI) in the Diagnosis of Myelodysplastic Syndrome (MDS) When Morphology Is Not Conclusive.

Immunophenotype in Chronic Myelomonocytic Leukemia: Is It Closer to Myelodysplastic Syndromes or to Myeloproliferative Disorders?.

Phenotypic Aberrations of Myeloid CD34+ Cells in Patients with Myelodysplastic Syndrome (MDS): Clinical Significance and Correlation with Cytogenetics Abnormalities.

Flow Cytometry Applications in the Diagnosis of Myelodysplastic Syndrome (MDS): Analysis of 45 Cases.

Email alerts

ASH Publications

American Society of Hematology

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Idiopathic Cytopenia of Undetermined Significance (ICUS): Impact of Flow Cytometry Immunophenotyping (FCI) in the Diagnosis of Myelodysplastic Syndrome (MDS) When Morphology Is Not Conclusive.

Immunophenotype in Chronic Myelomonocytic Leukemia: Is It Closer to Myelodysplastic Syndromes or to Myeloproliferative Disorders?.

Phenotypic Aberrations of Myeloid CD34+ Cells in Patients with Myelodysplastic Syndrome (MDS): Clinical Significance and Correlation with Cytogenetics Abnormalities.

Flow Cytometry Applications in the Diagnosis of Myelodysplastic Syndrome (MDS): Analysis of 45 Cases.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only